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The economic burden of cancer care for Syrian refugees: 
a population-based modelling study
Rima A Abdul-Khalek*, Ping Guo*, Forbes Sharp, Adrian Gheorghe, Omar Shamieh, Tezer Kutluk, Fouad Fouad, Adam Coutts, Ajay Aggarwal, 
Deborah Mukherji, Ghassan Abu-Sittah, Kalipso Chalkidou, Richard Sullivan, on behalf of the R4HC-MENA collaboration†
Summary
Background Cancer represents a substantial health burden for refugees and host countries. However, no reliable data 
on the costs of cancer care for refugees are available, which limits the planning of official development assistance in 
humanitarian settings. We aimed to model the direct costs of cancer care among Syrian refugee populations residing 
in Jordan, Lebanon, and Turkey.
Methods In this population-based modelling study, direct cost per capita and per incident case for cancer care were 
estimated using generalised linear models, informed by a representative dataset of cancer costs drawn from 
27 EU countries. A range of regression specifications were tested, in which cancer costs were modelled using different 
independent variables: gross domestic product (GDP) per capita, crude or age-standardised incidence, crude or age-
standardised mortality, and total host country population size. Models were compared using the Akaike information 
criterion. Total cancer care costs for Syrian refugees in Jordan, Lebanon, and Turkey were calculated by multiplying 
the estimated direct cancer care costs (per capita) by the total number of Syrian refugees, or by multiplying the 
estimated direct cancer costs (per incident case [crude or age-standardised]) by the number of incident cancer cases in 
Syrian refugee populations. All costs are expressed in 2017 euros (€).
Findings Total cancer care costs for all 4·74 million Syrian refugees in Jordan, Lebanon, and Turkey in 2017 were 
estimated to be €140·23 million using the cost per capita approach, €79·02 million using the age-standardised 
incidence approach, and €33·68 million using the crude incidence approach. Under the lowest estimation, and with 
GDP and total country population as model predictors, the financial burden of cancer care was highest for Turkey 
(€25·18 million), followed by Lebanon (€6·40 million), and then Jordan (€2·09 million).
Interpretation Cancer among the Syrian refugee population represents a substantial financial burden for host 
countries and humanitarian agencies, such as the UN Refugee Agency. New ways to provide financial assistance need 
to be found and must be coupled with clear, prioritised pathways and models of care for refugees with cancer.
Funding UK Research and Innovation Global Challenges Research Fund: Research for Health in Conflict-Middle East 
and North Africa region (R4HC-MENA).
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
In 2017, the UN Refugee Agency (UNHCR) recorded 
68·5 million people of concern worldwide,1 including 
25·4 million refugees, 40·0 million internally displaced 
persons, and 3·1 million people seeking asylum. The 
combined number of refugees and internally displaced 
persons—65·4 million—has more than doubled since 
2010 and almost tripled since 2000.2 Refugees represent 
a highly vulnerable population; they require specific 
support, and a major responsibility is placed on the inter-
national community and host countries to meet their 
needs.
Non-communicable diseases (NCDs) represent a sub-
stantial burden, in both refugee and host com munities, 
that requires humanitarian support. However, the 
traditional humanitarian and refugee health response 
has focused on the provision of health-care services to 
address communicable diseases.3 The millions of 
refugees and internally displaced persons moving in and 
out of war zones through the Middle East, Asia, and 
Europe illustrate the need to refocus the health response 
on NCDs. Among NCDs, cancer represents a particular 
challenge.4 Not only is it a leading cause of mortality, but 
the trajectory of care for many types of cancer requires a 
robust health system that can deliver and coordinate a 
wide range of services, such as screening programmes, 
diagnostic services, palliation, or treatment with surgery, 
radiotherapy, or chemotherapy.5
The growing prevalence of NCDs, especially in low-
income and middle-income countries, is characteristic of 
the so-called epidemiological transition.6 The pro portion 
of deaths that were due to NCDs in people aged 
30–70 years in Syria was 22% in 2016, and similar 
proportions were reported for Jordan, Lebanon, and 
Turkey.7 The international humanitarian global health 
communities have been slow to acknow ledge and 
address the rapid increase in NCDs that has accompanied 
the arrival into host countries of millions of refugees 
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from Syria.8 This delay has resulted in a care gap for 
NCDs that has only begun to be addressed in the past 
5 years.9 Much of this focus has been on cardiovascular 
diseases, hypertension, or diseases with severe and 
immediate outcomes if management is disrupted, such 
as provision of insulin for type 1 diabetes or dialysis for 
kidney disease.9–11 Cancer care, however, remains an 
acutely neglected part of the NCD refugee health 
response because of the financial costs involved and 
the health service capacity that is needed to provide 
adequate care.
UN agencies such as WHO and UNHCR provide 
leadership for refugee health, but strategic plans have 
only estimated aggregate costs for the health sector, and 
allocation of resources to cancer services is not clearly 
delineated. In addition, host nations often struggle to 
provide adequate cancer services for refugees, partially 
due to the additional fiscal and health-care resource 
strains put on health systems in nations with refugee 
populations.12 However, in several countries neighbouring 
Syria, the arrival of refugees has uncovered poorly 
developed pre-existing services and inadequate health 
system financing mechanisms, such as low health 
insurance coverage of local host populations and high 
out-of-pocket payments.13,14 For example, in Lebanon, 
only 42% of the Lebanese population are covered by 
public health insurance, and out-of-pocket payments 
represent 32% of total health expenditure; in Turkey, 
however, more than 90% of the population has public 
insurance and out-of-pocket expenditure represents 
16% of health expenditure (appendix 3 p 3).
Provision of cancer care for refugees in the Middle East 
and North Africa region has been particularly challenging 
due to rising costs of care globally and the scarcity of 
effective cancer control plans in host countries.15 In 
addition, the quality of epidemiological, service-use, 
treatment effectiveness, and cost data from local 
ministries of health is low, and access to UNHCR health 
registers is restricted. Cancer registration for Syrian 
refugees has been advocated to support international aid 
requests,16 but the process of cancer registration among 
refugees is not well established. Cancer registration 
among Syrian refugees fluctuates according to changes 
in funding for the registries in Jordan17 and other 
registries across the Middle East and North Africa 
region.18 In Lebanon, Syrian refugee cancer cases stopped 
being registered at the national cancer registry in 2015; 
thus, registered cancer cases might not be representative 
of the actual number of cases.19
For 246 approved cancer cases among refugees across 
Syria and Jordan, the mean expenditure approved per 
application was US$4626 (range $412–21 188) in 2011, 
and $3501 ($289–18 873) in 2012,20 but these costs 
encompass only half of the cancer care funding requests 
submitted to the UNHCR exceptional care committees. 
Given the scarcity of reliable data in the region, 
inadequate support for cancer care among refugees, and 
the fiscal and resource burden it presents for individuals 
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Research in context
Evidence before this study
The Syrian conflict has led to millions of individuals leaving the 
country as refugees. The impact of this refugee crisis on 
non-communicable diseases, such as cancer, is unknown. 
Although major efforts have been made to fund the health 
sector by the UN Refugee Agency (UNHCR) and partner 
non-governmental organisations (NGOs), no analyses of the 
costs of delivering cancer care have been done.
To identify studies reporting on the costs of cancer care in Syrian 
refugee host countries, we did a literature search of MEDLINE, 
Embase, and Global Health (all via Ovid) for articles published 
between Jan 1, 2012, and July 1, 2019, without language 
restrictions, to identify national estimates of direct costs for 
cancer care in Jordan, Lebanon, and Turkey. We searched for 
articles related to cancer (“cancer” or carcinom*” or oncolog*” 
or tumor*” or “neoplasm*”) and costs (“cost” or “economic” 
or “financ*” or “budget*” or “price*” or “pay*” or “reimburse*”) 
in the three host countries by searching the title, abstract, and 
keyword fields. We identified no cost-of-illness studies and less 
than 20 articles that focused on either specific cancer types or 
sites or on the cost of specific resources (eg, drugs). Previous 
cancer cost estimates were not directly comparable across the 
three countries, and they were insufficient to aggregate into the 
average cost per cancer case or per capita.
Added value of this study
To our knowledge, this is the first study to estimate the cost of 
cancer treatment for Syrian refugees in Jordan, Lebanon, and 
Turkey. We have estimated these costs using a model based on 
gross domestic product and total national population size. 
We used different approaches to estimate costs: an approach 
that did not include the incidence of cancer in host countries 
(cost per capita), and two approaches that adjusted for cancer 
incidence and estimated costs per incident cancer case (either 
crude or age-standardised). The findings provide supporting 
information for planning the cost requirements for funding for 
cancer care, a disease with complex treatment pathways, 
by UNHCR and partner NGOs for Syrian refugees.
Implications of all the available evidence
Our findings inform the dialogue between national 
governments, humanitarian actors, and donors on reducing 
cancer burden among refugees. The estimates of this study are 
important for decision making when planning funding for 
health care of refugees, and they contribute to the wider 
political economy evidence base on cancer care for refugees, 
internally displaced persons, and other vulnerable groups. 
Our estimated costs represent 11·0% of the total funding 
requested for the health sector by UNHCR and partner NGOs.
Articles
www.thelancet.com/oncology   Vol 21   May 2020 639
and host communities, generating estimates of the 
financial resources required to provide adequate care 
could help inform humanitarian resource planning and 
allocation.
We present an econometric analysis of the financial 
burden of Syrian refugees with cancer currently residing 
in Jordan, Lebanon, and Turkey. We aim to fill some of 
the existing information gaps and inform the ongoing 
dialogue among national governments, humanitarian 
actors, and donors towards decisive, coordinated action 
to reduce the cancer burden among refugees. Our 
approach could contribute to the wider political economy 
evidence base on cancer care for refugees, internally 
displaced persons, and other vulnerable groups.
Methods
Analysis framework
With use of a population-based model, we estimated the 
direct costs of treating all cancers per annum among 
4·74 million Syrian refugees residing in Jordan, Lebanon, 
and Turkey as of 2017.21 Cancer was defined here using 
the WHO International Classification of Diseases, tenth 
revision, codes C00–97. The cost of treatment was defined 
as the cost of direct services provided by the respective 
national health system, specifically the cost of drugs and 
the use of four categories of health service: community 
services, outpatient visits, emergency room visits, and 
days spent as an inpatient (eg, diagnostics, surgery, 
and radiotherapy). Total costs were calculated using 
three approaches as the product of the estimated cancer 
care cost (per capita, per incident cancer case [crude], or 
per incident cancer case [age-standardised]) and the total 
number of Syrian refugees or Syrian incident cancer 
cases, as appropriate, then summed across the three 
countries. Crude incident cancer cases reflected the 
incidence under the country’s respective age distribution, 
whereas the age-standardised incident cases had 
been standardised to a world standard population. All 
costs are expressed in 2017 euros (€). Prices were adjusted 
for inflation from 2009 to the most recent annual rate 
available (year-end 2017).22
Data sources
Given the poor availability of data to estimate cancer 
treatment costs for Syrian refugees, we made a pragmatic 
decision to use the validated cost dataset for cancer care 
in 27 EU countries (hereafter referred to as the EU cancer 
dataset or EU cancer cost analysis)23 to estimate the 
average cost per capita and per incident case for Syrian 
refugees in Jordan, Lebanon, and Turkey (appendix 3 p 4). 
The EU cancer cost analysis was based on data from 
several sources, including WHO, the Organisation for 
Economic Co-operation and Development, the Statistical 
Office of the European Communities (EUROSTAT), 
national ministries of health, and statistical institutes.
The six dependent variables derived from the EU 
cancer dataset were: number or frequency of health-care 
contacts (per 1000 population); cost per capita (drugs 
plus services); cost per capita (services); cost per capita 
(drugs); cost per incident case (crude); and cost per 
incident case (age-standardised; appendix 3 p 4). The 
original cost per capita (drugs plus services) variable was 
split into its two constituent parts on the basis of evidence 
that the costs of drugs are potentially highly variable, and 
are affected by the markets, regulation practices, and 
other factors.24,25 We included the number of health-care 
contacts based on the hypothesis that there was a positive 
correlation between the frequency of service use and the 
burden of cancer within a given population.
The cost per incident case was used to adjust costs at 
the final calculation stage and reflected the burden of 
cancer via the incidence of a given target population. 
This strategy was considered particularly necessary 
because there is a marked difference in cancer incidence 
between the EU and the Middle East and North Africa 
countries under study. Three data sources were used to 
calculate this cost (appendix 3 p 7): the total cost for 
cancer services at the national level (appendix 3 p 4);23 
national population figures (appendix 3 p 5);26 and 
national cancer incidence data (appendix 3 p 6).27 The 
crude and age-standardised incidences in this study refer 
to the reported incidence data for the year 2017.
Six predictors of cancer care costs were selected on 
the basis of positive associations identified in the EU 
cancer cost analysis: gross domestic product (GDP) per 
capita, total country population size, crude incidence, 
age-standardised incidence, crude mortality, and age-
standardised mortality (appendix 3 p 8). Other health 
system financing variables, such as total health expen-
diture and public expenditure per capita, are correlated 
with GDP per capita,28 and as such were omitted. We 
also considered using the density of radiotherapy 
equipment as a predictor of cost, but EUROSTAT data 
are reported from 2015 onwards (versus the reference 
year of 2009 in the EU cancer cost analysis) and data 
were missing for seven countries; therefore, it was 
excluded.23
Estimation of cancer costs
First, using regression diagnostic techniques, we tested 
for outliers within the EU cancer dataset with use of 
residual and standardised residual versus fitted value 
plots. We tested for a normal distribution of residuals 
using a normal Q-Q plot and tested for influential 
observations (ie, countries or other observations that, 
when introduced into the model, induce significant 
changes to the model coefficients or regression line) 
using Cook’s distance plot. Using generalised linear 
models, single variable and multivariable regression 
models were constructed to predict average costs of 
cancer care in the EU cancer dataset, using cost per 
capita and cost per incident case approaches. We used a 
variety of distributions (normal, inverse Gaussian, 
gamma) and compared the different models using the 
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log and square-root links. The regression specifications 
with the best predictive performance were used to 
estimate costs of cancer care per capita and per incident 
case in Jordan, Lebanon, and Turkey in 2009, in euros, as 
per the EU cancer dataset, and later adjusted for 
inflation.22 These estimates were then multiplied by the 
corresponding number of individuals from the Syrian 
population (ie, the number of Syrian refugees in each 
host country), and crude or age-standardised incidence 
in the Syrian population (which is expected to be the 
same in Syrian refugees), to estimate total cancer care 
costs among Syrian refugees in each country. When 
performing the out-of-sample pre dictions for cancer care 
costs in Jordan, Lebanon, and Turkey (ie, when values for 
some predictors [eg, GDP] were not in the range of values 
used for building the models in the EU cancer dataset), 
predictors were those of the host country.
Analyses were done using R statistical package 
version 3.6.0. Model goodness-of-fit was measured using 
residual deviance (by χ² test) and regression models were 
compared using the Akaike information criterion, whereby 
models with a lower Akaike information criterion were 
considered to have a better fit. Given the small size of our 
dataset (<30 data points), we sought to prevent overfitting 
by specifying parsimonious models with up to two 
predictors.
Independent variables were tested in the final models 
in terms of both statistical and practical significance. 
Statistical significance was calculated at an α level of 
0·05.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data and had final responsibility for the decision to 
submit for publication.
Results
To understand the validity of our models we did a series 
of analyses to look at the distribution of variables. The 
distribution of most dependent variables was right-
skewed (ie, not normally distributed), with drug cost per 
capita closer to normal distribution than other variables 
(appendix 3 p 10). Among the independent variables, the 
crude and age-standardised incidence and mortality 
variables were normally distributed; however, GDP per 
capita and total population were right-skewed (appendix 3 
p 10). Therefore, for prediction purposes, log-transformed 
GDP and log-transformed total population size values 
were included in the models.
For each of the dependent variables, associations were 
tested with six independent variables. The economic 
variable GDP per capita showed a strong positive 
correlation with all dependent variables containing a cost 
component (appendix 3 pp 11–13). An association was 
also noted between epidemiological variables (incidence 
and mortality) and the different types of costs, particularly 
for age-standardised mortality and age-standardised inci-
dence. The dependent variable cost per capita (drugs plus 
services) showed stronger associations with almost all 
independent variables than did either of the component 
costs (drugs or services) when analysed in isolation 
(appendix 3 pp 11–14). All independent variables showed 
weak associations with the dependent variable health-
care contacts (data not shown); therefore, it was excluded 
from additional models.
All cost variables were strongly correlated with each 
other (correlation coefficients 0·80–0·98), with the excep-
tion of the correlation between drug cost and service cost 
(0·68; appendix 3 p 14). Inde pendent variables (incidence, 
mortality, GDP per capita, and country population size) 
generally showed weaker corre lations with each other 
than did the cost variables (appendix 3 p 14).
Based on the associations between costs and inde-
pendent variables, three costs were selected (cost per 
capita [drugs plus services], cost per incident case [crude], 
and cost per incident case [age-standardised]) to be 
modelled with the four independent variables that 
showed higher levels of association: log GDP, log 
population size, age-standardised incidence, and age-
standardised mortality.
After examining regression diagnostics in the EU 
dataset (Cook’s distance plot for outliers, Q-Q plots for 
normality in response distribution, and plot of deviance 
residuals vs fitted values for linearity), Luxembourg and 
Greece were identified as outliers and excluded from the 
cost per capita and cost per incident case models, 
respectively.
All models tested the association between the 
three selected costs and four independent variables 
(models 1–15; appendix 3 pp 15–17). The model for cost 
per capita (model 8) and the model for both cost per 
incident case (crude) and cost per incident case (age-
standardised; model 5) had the lowest Akaike information 
criterion across the three dependent variables. Adding 
more variables did not appear to bring additional gains 
and risked overfitting the models (data not shown). The 
final step of the modelling process adjusted the three 
estimated costs for either the population size or the 
cancer incidence of the refugee population, and for 
inflation of prices.
For regression models that included country GDP and 
total population size as predictors in Jordan, Lebanon, 
and Turkey, we estimated the total cost per capita using 
model 8, and the total cost per incident case (crude) and 
total cost per incident case (age-standardised) using 
model 5 (table). The per capita model resulted in a total 
cost of €140·23 million for the Syrian refugee population 
in the three host countries. This estimate does not take 
into account the cancer incidence in Syrian refugees, 
which was lower than that in the European countries 
studied. For practical reasons that outweigh the theo-
retical limitations, and because incidence is more 
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representative than the whole population size (ie, the per 
capita method) of the actual burden among cancer cases, 
we also report costs using the cost per incident case 
(crude or age-standardised) approach. The estimated 
total cost using the per incident case (age-standardised) 
method was €79·02 million, and using the per incident 
case (crude) method was €33·68 million. The age-
standardised estimate of €79·02 million translates to a 
cost of €11 417 per age-standardised incident case when 
con sidering a total of 6920 incident cases estimated in 
the three hosting countries. For the crude incident cases, 
which represent the actual cancer cost burden (reflecting 
the current age structure of the Syrian population), the 
estimated annual cost for providing cancer-specific care 
to the 4·74 million Syrian refugees in Jordan, Lebanon, 
and Turkey was €33·68 million, comprising costs of 
€2·09 million in Jordan, €6·40 million in Lebanon, and 
€25·18 million in Turkey (table).
Discussion
In this study, we used two models to estimate the costs of 
cancer care for Syrian refugees residing in Jordan, 
Lebanon, and Turkey. The model that used cost per capita 
estimated a total cost of €140·23 million for the Syrian 
refugee population in the three host countries. The 
model that used cost per incident case estimated a total 
cost of €33·68 million using crude incidence and 
€79·02 million using age-standardised incidence. We 
modelled the costs of cancer treatment in patients treated 
comprehensively and according to context-specific 
clinical guidelines applied to the refugee population in 
the Middle East and North Africa region using global and 
EU datasets. The estimated costs of care were for Syrian 
refugees residing in Jordan, Lebanon, and Turkey in 
particular, but they can be used to reflect on the needs of 
the wider refugee population.
The positive correlation between cancer-related costs 
and the GDP of the country was expected, having been 
identified in the EU cancer cost analysis23 and other 
analyses.29 The correlation remains when health costs are 
expressed relative to at least one indicator of the burden 
of cancer in a population, such as cancer incidence or 
population size. Moreover, cancer costs in high-income 
countries currently focus on expensive technologies and 
highly specialised services.30 Our model was adjusted for 
both GDP and the total population size, and resulted in 
estimated costs that were lower than most high-income 
countries in Europe. The use of age-standardised 
incidence allowed for the control of differing demo-
graphic profiles across samples and is considered a 
preferable method for corroboration purposes, because a 
dataset derived from one global region (the EU) is being 
used to estimate costs for a population in another region. 
The substantially higher cost per incident case (age-
standardised) than cost per incident case (crude) can be 
attributed to the fact that the refugee Syrian population, 
and the Syrian population in general, is young, with 
more than 50% of the population distribution between 15 
and 64 years of age, which differs from the world standard 
population.21,31
The global refugee situation poses an enormous 
challenge to fragile health systems, and requires upscaling 
of the knowledge base and skills of health-care providers to 
respond to the needs of individuals, and must be addressed 
in the context of broader humanitarian and political 
issues.32 Access to cancer services for refugees varies in 
Jordan, Lebanon, and Turkey. The settlement of most 
Syrian refugees outside of camps33 highlights the need to 
integrate cancer care into the existing health systems, and 
increase national capacities to provide cancer care to both 
nationals and refugees.34,35 Additional care for refugees, if 
inte grated into such systems, would require changes and 
upscaling of capacities and resources. In Jordan for 
example, availability and accessibility to opioids for the 
general population are interrupted, and information on 
diagnosis and prognosis is commonly concealed from 
patients.36
Although specific details of cancer services in Jordan, 
Lebanon, and Turkey are not known (and are there-
fore difficult to corroborate), poor cancer outcomes due 
to low cancer-related health spending is a plausible 
interpretation of previous findings, considering the 
Number of 
Syrian refugees*
Incident cases 
(crude)
Incident cases 
(age-standardised)
Average costs, €† Total costs, €†
Cost per capita Cost per 
incident case 
(crude)
Cost per incident 
case 
(age-standardised)
Total cost per 
country (per 
capita method)
Total cost for 
cancer cases 
(crude incidence 
method)
Total cost for 
cancer cases 
(age-standardised 
incidence method)
Jordan 661 114 682 965 1·4 2779 4367 1 041 710 2 094 721 4 657 732
Lebanon 1 001 051 1033 1461 19·2 5608 8910 21 348 457 6 401 953 14 385 792
Turkey 3 079 914 3178 4494 34·6 7169 12 075 117 835 418 25 179 655 59 973 338
Total 4 742 079 4893 6920 ·· ·· ·· 140 225 585 33 676 329 79 016 862
Regression dataset excludes Luxembourg as an outlier in the cost per capita model, and Greece in the cost per incident case models. Gross domestic product and total population are predictors in all models. 
The incidence per 100 000 population (crude or age-standardised) can be calculated by dividing the incident cases by the Syrian refugee population size and multiplying by 100 000. *Since June 7, 2017 (except in 
Lebanon, where official registration was halted in May, 2015). †From 2009 to 2016 (most recent annual rate available); a conversion factor of 1·105102 was used to adjust for inflation of prices during this period.
Table: Estimated costs for cancer-specific health-care services in the Syrian refugee population in Jordan, Lebanon, and Turkey for 2017
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associations that have been identified between cancer 
outcomes and the availability of cancer services.37,38 The 
weak association between health-care contacts and 
explanatory variables could be explained by the frequency 
of health service use being affected by different health-
care-seeking behaviours and different levels of acces-
sibility of services in host countries; alternatively, the 
method applied in the EU cancer cost analysis to measure 
health-care contacts might not be representative of the 
actual use of services for cancer-specific support in 
Jordan, Lebanon, and Turkey.
In the context of humanitarian funding for the Middle 
East and North Africa region, the estimated overall cost 
of €33·68 million (approximately $38 million) across the 
three host countries would constitute 11·0% of the 
annual budget of $345 million requested for Syrian 
refugees in 2017 for Jordan, Lebanon, and Turkey. In 
reference to what is actually funded, this represents 
20·3% of the $187 million of funding for the health 
sector in 2017 for Syrian refugees in the same countries.39 
Although a comprehensive analysis of cancer costs in the 
three Middle East and North Africa countries is 
unavailable, previous studies have estimated specific 
costs for patients with cancer, and results are similar to 
our estimates for unit costs. For example, the direct 
medical cost for treating colorectal cancer in Jordan was 
$10 114 per patient in 2014 (equivalent to €7625).40 This 
amount is slightly higher than our finding of €4367 per 
incident case (age-standardised), although our estimate 
is not specific to colorectal cancer. For Syrian refugees in 
Jordan, the total cancer costs incurred at one centre were 
$11·4 million (€9·7 million) over 8 years (2011–18),17 
which is higher than our estimate of $4·66 million at this 
centre. In Lebanon, drug costs were $6475 per patient, as 
an average of expenditure during the years 2008–2013.41 
When comparing the cost per incident case (age-
standardised) between Middle East and North Africa and 
EU countries, estimated costs for Lebanon and Turkey 
were close to those in Latvia and Romania (appendix 3 p 4), 
whereas the cost for Jordan was lower, and close to that 
for Bulgaria; therefore, for all three host countries, the 
estimated costs for cancer care among Syrian refugees 
were among the lowest amounts spent by countries 
providing cancer care through their health systems. 
Countries such as Bulgaria and Slovenia had similar 
costs of €124 million and €145 million, respectively, but 
the cancer incidence in these countries was higher 
(appendix 3 p 4).
A limitation of this study was the sample selected for 
analysis, which included only refugees and might not 
be representative of the wider population of persons of 
concern, as defined by the UNHCR. With use of esti-
mates of the number of persons of concern from the 
literature, an increase in the generated estimate would be 
expected. The cost estimates used to predict cancer costs 
were transferred from European datasets, where reported 
incidence is much higher than in the Middle East and 
North Africa region, resulting in high cost per capita 
estimates. Because of substantial variations in care 
provision between cancer services in each country and 
across countries, individual-level resource use data could 
be collected and used in future studies to ensure that 
more accurate cost data are calculated, rather than 
estimated with average costs. Additionally, the types of 
cost estimated might not represent the necessary funds 
for cancer control programmes or systems, but instead 
represent the patient-centred costs; as such, they ignore 
the costs of capital investments needed to provide the 
necessary services. From this perspective, our results 
are underestimates. The European cancer cost dataset 
does not distinguish between cancer stages, and therefore 
our estimates do not account for the proportion of cases 
diagnosed at each stage in each country. Although 
evidence suggests that costs of care increase with stage at 
diagnosis, for example in breast cancer,42 there are 
differences across cancer types in terms of selecting the 
cost predictors in the regression models.43 We adopted a 
pragmatic approach aligned with the European cancer 
cost analysis, given the scarce evidence on country-level 
predictors of cancer care costs, particularly in low-income 
and middle-income countries. Further research should 
prioritise improving the performance of cross-country 
cancer cost models to improve the accuracy of such 
estimates when local data are not yet available.
When considering funding for cancer care among 
refugees in wider international efforts to support cancer 
care, efforts are disorganised and inadequately funded.16 
Previous work from Iraq showed that of 164 refugees 
diagnosed with a primary cancer, 79 (48%) had attempted 
resettlement, indicating possible treatment insecurity 
and a lack of supportive cancer care.44 However, cancer 
among Syrian refugees has remained largely unaddressed 
in the humanitarian response, mostly because of 
UNHCR financial constraints.17 Evidence from the Global 
Burden of Disease Study described cancer control in 
the Eastern Mediterranean region as having deficits 
in prevention, detection, diagnostics, treatment, and 
palliation.5 Refugee cancer care is inefficient when taking 
into account the pre-existing vulnerability of the host 
populations in Jordan, Lebanon, and Turkey.
Our results provide an initial indication of the magni-
tude of the cancer burden among Syrian refugees and can 
inform the regional multi-stakeholder dialogue on 
coordinating action plans, scaling up existing initiatives, 
and investing in infrastructure and data systems. Funding 
for cancer needs to go beyond current UNHCR financing 
mechanisms; sustainable, inclusive, and com prehensive 
financing mechanisms under the universal health 
coverage umbrella are necessary to account for the health 
needs of refugee populations and host communities, 
building on the political commitment taken by the 
governments of Jordan, Lebanon, and Turkey towards 
universal health coverage. Evidence from countries with 
privatised health-care systems, such as India, show that 
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low health insurance coverage for patients with cancer 
leads to catastrophic health expen ditures and families 
falling into poverty.45 The Iraq and India case studies 
indicate that refugees travelling to different countries 
seeking cancer care in particular can accelerate financial 
catastrophe because of additional costs associated with 
travel and mobility. Context-specific treatment protocols 
and guaranteed access and continuity of treatment will be 
crucial for improving models of cancer care in conflict-
affected regions.46 The use of resource-stratified guide-
lines could help to ensure better access to, higher quality 
of, and fewer disparities in cancer care.16
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